EnVision CF Multicenter Study of Glucose Tolerance in Cystic Fibrosis

Status: Recruiting

Eligibility Criteria

Sex: All
Age: 6 Years and over
This study is NOT accepting healthy volunteers

Inclusion Criteria:

1. Age >/= 6 years 2. Diagnosis of cystic fibrosis 3. CF patients regularly attending the CF centers 4. Clinically stable in previous 3wks:

• absence of major clinical events including pulmonary exacerbations,

• no change in their habitual treatment regimen including introduction of antibiotics or steroids in the past 3 weeks

Exclusion Criteria:

1. Diagnosis of type 1 diabetes, type 2 diabetes, or MODY 2. Organ transplantation 3. new diagnosis of CFRD in the past 6 months 4. antidiabetic treatment in past 6 mos (insulin or oral hypoglycemic agents) -patients with previous CFRD diagnosis, but not currently taking insulin/glucose-lowering medications for at least 6 months should be included 5. pulmonary exacerbation associated with systemic steroid requirement in the last 6 months 6. on CFTR corrector less than 6 months prior to enrollment

Conditions & Interventions

Interventions:
Diagnostic Test: Oral glucose tolerance test, Diagnostic Test: Continuous glucose monitoring, Diagnostic Test: Dexa scan
Conditions:
Cystic Fibrosis-related Diabetes
Keywords:
cystic fibrosis, insulin, glucose, children, abnormal glucose tolerance, impaired glucose tolerance, indeterminate glycemia, diabetes

More Information

Description: The purpose of this research study is because Cystic Fibrosis Related Diabetes (CFRD) has been identified by the cystic fibrosis (CF) community as one of the top ten priorities for CF research. We know that high blood sugars caused by not enough insulin lead to worse lung function in CF even before diabetes develops. However, we do not know which people with abnormal blood sugars will have long term problems.
Contact(s): Amir Moheet - mohee002@umn.edu
Principal Investigator: Amir Moheet
Phase: N/A
IRB Number: STUDY00004854
System ID: NCT03650712